IF shows positive staining in paraffin-embedded human colon cancer. Anti- TIM-3 (Alexa Fluor® 700 Conjugate) antibody was used at 1/100 dilution (magenta) and incubated overnight at 4°C. Counterstained with DAPI (Blue). Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IF staining protocol.
Product Details
Product Details
Product Specification
Host | Rabbit |
Antigen | TIM-3 |
Synonyms | Hepatitis A virus cellular receptor 2, HAVcr-2, T-cell immunoglobulin and mucin domain-containing protein 3 (TIMD-3), T-cell immunoglobulin mucin receptor 3 (TIM-3), T-cell membrane protein 3, CD366, HAVCR2, TIMD3 |
Immunogen | Recombinant Protein |
Location | Cell membrane |
Accession | Q8TDQ0 |
Clone Number | S-1450-21 |
Antibody Type | Recombinant mAb |
Isotype | IgG |
Application | IF |
Reactivity | Hu |
Purification | Protein A |
Concentration | 2 mg/ml |
Conjugation | Alexa Fluor® 700 |
Physical Appearance | Liquid |
Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
IF | 1:100 | Hu |
Background
TIM-3, also known as Hepatitis A virus Cell receptor 2 (HAVCR2), is a transmembrane protein and a member of the TIM protein family, which plays a crucial role in immune response regulation. It is expressed on various immune cells, including CD8+ T cells, Th1 cells, regulatory T cells (Tregs), dendritic cells (DCs), natural killer (NK) cells, monocytes, and macrophages. TIM-3 functions as an inhibitory receptor and is associated with T cell exhaustion in chronic infections and cancer. It has been identified as a promising target for cancer immunotherapy, as its blockade can enhance antitumor immunity. The receptor interacts with several ligands, including Galectin-9, CEACAM-1, phosphatidylserine (PtdSer), and High Mobility Group Box 1 (HMGB1). TIM-3 also plays a role in the clearance of apoptotic bodies by interacting with PtdSer on the surface of apoptotic cells. Recent studies have shown that targeting TIM-3 on DCs might be more critical for enhancing antitumor immunity than targeting it on T cells. Furthermore, combined blockade of TIM-3 and PD-1 has shown synergistic effects in reducing tumor growth in various mouse tumor models, suggesting that the combination therapy might be a promising approach for cancer treatment.
Picture
Picture
Immunofluorescence
IF shows positive staining in paraffin-embedded human tonsil. Anti- TIM-3 (Alexa Fluor® 700 Conjugate) antibody was used at 1/100 dilution (magenta) and incubated overnight at 4°C. Counterstained with DAPI (Blue). Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IF staining protocol.
